Biomarker ID | 1141 |
PMID | 23798998 |
Year | 2013 |
Biomarker | let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(let-7a):- nucleoplasm; regulation of RNA metabolic process; DNA-binding transcription factor activity, RNA polymerase II-specific; regulation of nucleic acid-templated transcriptionregulation of transcription, DNA-templated Pathways Include(let-7c):- regulation of RNA metabolic process; regulation of nucleic acid-templated transcription; regulation of RNA biosynthetic process; RNA biosynthetic process; regulation of transcription, DNA-templated Pathways Include( miR-515-3p):- synapse; DNA-binding transcription factor activity; transcription regulatory region DNA binding; transferase activity; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-515-5p):-DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; RNA biosynthetic process; regulation of RNA biosynthetic process; regulation of nucleic acid-templated transcription |
Experiment | Clinical progression free survival (CPFS) Vs. clinical failure (CF) |
Type of Biomarker | Prognostic |
Cohort | 7 patients in High Risk PCa with CPFS and 6 which were high risk with Clinical Failure were included in the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | microarray |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | let-7a, let-7b, let-7c, miR-515-3p, miR515-5p, miR-181b, miR-146b, miR-361 |